GPC3 and hepatocellular carcinoma: In 2022, Jiang et al. proposed GPC3 as a biomarker for HCC diagnosis and prognosis [7], and in 2020, Guo et al. showed that GPC3 is a promising candidate for HCC diagnosis and prediction of poor prognosis [8].